Nancy Lurker - Feb 9, 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
President & CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2022
Transactions value $
$0
Form type
4
Date filed
2/11/2022, 03:38 PM
Previous filing
Nov 17, 2021
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +17.5K +16.45% $0.00 124K Feb 9, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -17.5K -33.33% $0.00 35.1K Feb 9, 2022 Common Stock 17.5K $0.00 Direct F2
transaction EYPT Restricted Stock Units Award $0 +60K $0.00 60K Feb 9, 2022 Common Stock 60K $0.00 Direct F3
transaction EYPT Stock Option (Right to Buy) Award $0 +240K $0.00 240K Feb 9, 2022 Common Stock 240K $10.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,019 shares acquired on January 31, 2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
F3 These restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F4 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.